Classification of Nicotine Vapor and Tobacco Businesses

Sep.29.2022
Classification of Nicotine Vapor and Tobacco Businesses
Chesterfield County struggles to classify stores selling nicotine vapor and tobacco products, including whether they are similar to convenience stores.

Is there an ongoing issue: Are electronic cigarette shops the same as convenience stores?


The Planning Department of Chesterfield County held a work meeting on September 22 to discuss the issue of accurately categorizing businesses that sell nicotine vapor and tobacco products. The challenge lies in determining how to handle shops that not only sell, but also allow sampling of their products.


Due to the rapidly changing legal and cultural norms both within the state and across the country, there are many issues surrounding businesses in Virginia that differ from those in other states.


Brett Meadows, a senior planner, presented the information again to the committee by reviewing the discussions, issues, and action plans from the August work meeting.


Last month, planners conducted a review of zoning regulations allowing such companies to operate as convenience stores as they are currently classified separately within commercial zones.


According to the Meadows report, planners have been working with the community promotion department of the county since August to consider how to handle the signage of retail electronic cigarette and tobacco stores. From these discussions, planners have proposed a draft proposal on how to standardize, communicate and enforce future signage regulations.


Signage is a source of revenue for some of these businesses," noted Meadows. "Different vendors will pay to have their signs placed in storefront windows." Limiting the use of signage for e-cigarette shops may overlap with other businesses such as grocery stores or pharmacies, which sell products rather than sponsorships. He explained that existing zoning regulations do not specifically acknowledge or permit the sale and consumption of nicotine vapor products, but the definition of "convenience store" has been interpreted to include e-cigarette shops within commercial zoning districts.


According to data from Meadows cited by the Virginia Department of Behavioral Health and Developmental Services, Chesterfield has 235 locations - encompassing a wide range of retail businesses - selling nicotine vapor and tobacco products. In comparison, more than 120 of the 133 areas reported in Virginia have a higher concentration of businesses.


He stated that planners are working hard to define terms such as "recreational substances" and "recreational substance on-site usage" when developing a unique language for operating nicotine e-cigarettes. Meadows explained that these substances may include products from the industry's assistance but do not include marijuana that is governed by state and federal laws.


He added that the regulations, including the language drafted by the planners, will immediately identify nine county enterprises that are not complying with the rules.


Andrew Gillies, the Planning Director, described to the committee the "impossible" challenge of trying to classify the recreational use of nicotine vapor products. "As employees, we are focused on the on-site consumption aspect as much as possible," said Gillies.


He added, "I believe there needs to be a broader definition of 'entertainment substances' in order for us to have a clearer definition of on-site consumption of these substances. So, all these parts come together, I just want you all to know the direction. We are somewhat disregarding the retail industry, except for possibly better logo control and enhanced cooperation with the community, and some shopping center owners just want to better understand how to market these products.


Gillies informed the commissioner that the language formulated by the planners allows the county some flexibility in designating additional substances, which can be added to the defined sub-clauses, depending on how the cannabis issue is settled at the federal level.


In the end, the committee members voted to launch a new zoning ordinance in October. The proposed timeline by the Planning Department focuses on the new zoning regulations for nicotine vapor and tobacco companies, with a final goal of 2023. The committee members aim to hold open public hearings before this date.


Statement:


This article is compiled from third-party information and is intended for industry-specific communication and learning purposes.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the truthfulness or accuracy of the article's content. The translation of this article is only intended for industry communication and research purposes.


Due to limitations in our translation abilities, the translated article may not fully capture the intended meaning of the original. Please refer to the original text for accurate information.


2FIRSTS is fully aligned with the Chinese government's position on any domestic, Hong Kong, Macao, Taiwan, and foreign-related statements and views.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Japanese Addiction Psychiatrist Says Complete Abstinence Is Not Always the Goal of Harm Reduction | 2Firsts Interview
Japanese Addiction Psychiatrist Says Complete Abstinence Is Not Always the Goal of Harm Reduction | 2Firsts Interview
Complete abstinence is not always the goal of addiction treatment under a harm-reduction approach, Japanese psychiatrist Tomohiro Shirasaka told 2Firsts in Manila. In the interview, he discussed patients' quality of life, Japan's shift towards heated tobacco products, and the challenges of quitting smoking for people with mental illness. Drawing on addiction treatment work in the Philippines, he advocated support rather than punishment and questioned whether fear-based health warnings effectively address the reasons people continue smoking.
Nov.10
German Bundestag Passes Tobacco Tax Hikes: Vape Liquid Duty to Reach €0.44/ml, Heated Tobacco Taxes to Rise and Cigarettes Seen Near €12 a Pack
German Bundestag Passes Tobacco Tax Hikes: Vape Liquid Duty to Reach €0.44/ml, Heated Tobacco Taxes to Rise and Cigarettes Seen Near €12 a Pack
Germany's Bundestag passed amendments to the Tobacco Tax Act on October 15, 2026, setting out annual excise tax increases from 2027 through 2030 for e-cigarette liquids, heated tobacco, cigarettes and other tobacco products. Under the Finance Committee's amended bill, duty on qualifying e-liquids will rise from €0.32/ml in 2026 to €0.44/ml in 2030, an increase of 37.5%. Heated tobacco will retain its tax calculation based on 80% of the corresponding cigarette excise duty. The average price of a 20-cigarette pack is projected to approach €12 by 2030, with some brands potentially reaching €14. The legislation is projected to generate approximately €11.8 billion in additional tax revenue over four years and remains subject to further legislative procedures.
Regulations
Oct.19
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
India Steps Up Nicotine Pouch Enforcement as ZYN, White Fox Circulate and Drug Panel Urges Halt to New Nicotine Formulations
India Steps Up Nicotine Pouch Enforcement as ZYN, White Fox Circulate and Drug Panel Urges Halt to New Nicotine Formulations
India's Ministry of Health and Family Welfare has directed states to step up enforcement against nicotine pouch sales, citing increased availability through online and offline channels and concern about nicotine exposure among children. Reuters reported that international brands including ZYN and White Fox are being sold in India. A study led by ICMR-NICPR found pouches in seven of 10 surveyed locations and identified 68 brands and 445 flavors online. Separately, India's Drugs Technical Advisory Board recommended in August that no new nicotine formulation be approved.
Regulations
Sep.28 by 2Firsts Perspectives
Why Does JPMorgan Favor BAT Over Philip Morris Despite Forecasting Slower Growth of 3.9% Versus 6.2%?
Why Does JPMorgan Favor BAT Over Philip Morris Despite Forecasting Slower Growth of 3.9% Versus 6.2%?
JPMorgan resumed equity research coverage of British American Tobacco (BAT), Philip Morris International (PMI) and Imperial Brands in November 2026, assigning BAT an Overweight rating and the other two companies Neutral ratings. The bank forecasts like-for-like sales growth of 3.9% for BAT and 6.2% for PMI in 2027, but estimates the two companies will trade at approximately 11 times and 21 times 2027 earnings, respectively. JPMorgan cited BAT's improving position in US nicotine pouches and vaping products as a driver of its investment outlook. BAT reported a 220% constant-currency increase in US modern oral nicotine revenue in the first half of 2026, while PMI's ZYN US shipments returned to growth in the third quarter. Imperial expects NGPs to represent 4% to 5% of sales and has expanded its oral portfolio through acquisitions.
Capital Markets
Nov.12
Product|AIR Files U.S. PMTA for Crown Switch. Can Greentank's Chip Technology Deliver a Compliance and Competitive Advantage?
Product|AIR Files U.S. PMTA for Crown Switch. Can Greentank's Chip Technology Deliver a Compliance and Competitive Advantage?
AIR Global PLC (NASDAQ: AIIR) announced on November 5, 2026, that it had submitted a Premarket Tobacco Product Application (PMTA) to the U.S. Food and Drug Administration (FDA) for Crown Switch, its rechargeable pod vape platform. First launched in Germany in November 2025, the device uses Quantum Chip atomization technology developed by Canadian vaporization technology company Greentank Innovations. German retail versions feature 2mL prefilled pods containing 18mg/mL nicotine in six flavors, while AIR has separately tested two 5% nicotine formulations intended for U.S. development. AIR invested $20 million in Greentank in July and reported approximately $3.4 million in U.S. PMTA-related regulatory costs for the first nine months of 2026. The Crown Switch application has been submitted, but the FDA has not granted marketing authorization.
product
Nov.13